

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 12-2001)	ATTORNEY'S DOCKET NUMBER								
TRANSMITTAL LETTER TO THE UNITED STATES	20740-242738								
DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5 10/009059								
CONCERNING A FILING UNDER 35 U.S.C. 371									
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/EP00/05127 June 5, 2000	PRIORITY DATE CLAIMED June 4, 1999								
TITLE OF INVENTION RECOMBINANT FUSION PROTEIN, (VACCINE) COMPOSITION CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF									
APPLICANT(S) FOR DO/EO/US LOHMANN ANIMAL HEALTH GMBH & CO. KG									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.									
This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
The US has been elected by the expiration of 19 months from the priority date (Article 31).									
A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
a. is attached hereto (required only if not communicated by the International Bureau).									
= · · · · · · · · · · · · · · · · · · ·	b. has been communicated by the International Bureau.								
c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
a. X is attached hereto.									
b. has been previously submitted under 35 U.S.C. 154(d)(4).	35								
Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))									
 a. are attached hereto (required only if not communicated by the International Communicated by the International Communicated Section 2018). 	a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.									
c. have not been made; however, the time limit for making such amendments has NOT expired.									
d. have not been made and will not be made.									
3. 🔼 An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).									
9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. An English lanugage translation of the annexes of the International Preliminary Article 36 (35 U.S.C. 371(c)(5)).									
Items 11 to 20 below concern document(s) or information included:									
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
12. An assignment document for recording. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.								
13. A FIRST preliminary amendment.									
14. A SECOND or SUBSEQUENT preliminary amendment.	•								
15. A substitute specification.									
16. A change of power of attorney and/or address letter.									
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.									
18. A second copy of the published international application under 35 U.S.C. 154	(d)(4).								
A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
0. Other items or information:									

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/009059 INTERNATIONAL APPLICATION NO. PCT/EP00/05127				ATTORNEY'S DOCKET NUMBER 20740-242738				
21. The following fees are submitted:				CAL	CULATIONS	PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):								
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.485(a)2)) paid to USPTO and International Search Report not prepared by the EPO or JPO								
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00								
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)								
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				<u> </u>		1		
ENTER APPROPRIATE BASIC FEE AMOUNT =				2		ļ		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$		<u> </u>	
CLAIMS	NUMBER FILI		NUMBER EXTRA	RATE	\$			
Total claims	- 20			x \$18.00	\$		ļ	
Independent claims	-3		- Pro- blox	x \$84.00	\$		 	
MULTIPLE DEPEN				+ \$280.00	\$			
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				s				
			SI	BTOTAL =	s		t	
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$			
TOTAL NATIONAL FEE =				s		†		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				s				
TOTAL FEES ENCLOSED =					s		 	
					Amo	unt to be refunded:	s	
						charged:	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.								
b. Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.06-0029. A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card								
information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO: Paul W. Busse								
Faegre & Benson LLP SIGNATURE								
					V. Busse			
90 South Seventh Street NAME								
Minneapolis, MN 55402-3901 32,40								
l				REGISTR	ATION	NUMBER		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GEORG BALJER et al.

Serial No.: 10/009,059

Filed: December 3, 2001

For: RECOMBINANT FUSION PROTEIN,

(VACCINE) COMPOSITION
CONTAINING THE SAME AND
METHOD FOR THE PRODUCTION

THEREOF

Examiner:

Group Art Unit:

Docket No.

20740-242738

Box Patent Application

Commissioner for Patents Washington, D.C. 20231 EXPRESS MAIL LABEL NO. EL210854772US

I CERTIFY THAT, ON FEBRUARY 28, 2002, THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL POST OFFICE TO ADDRESSE SERVICE UNDER 37 C.F.R. 1.10 IN AN ENVELOPE 4DORESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, J.C. 2023.1

TRANSMITTAL LETTER

Enclosed for filing are the following papers in connection with the above-identified patent application:

- Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371;
- 2. Declaration and Power of Attorney;
- 3. English Translation of the International Application;
- 4. PCT International Preliminary Examination Report;
- Postcard.

A self-addressed return postcard in accordance with M.P.E.P. Section 503 itemizing all of the above-referenced documents filed with the United States Patent and Trademark Office. In the event the amount submitted herewith is insufficient in any respect, the Commissioner is hereby authorized to charge the balance needed to our Deposit Account No. and is requested to notify us of the same.

Respectfully Submitted,

GEORG BALJER et al.

By:

Paul W. Busse, #32,403 Special Counsel FAEGRE & BENSON LLP 2200 Wells Fargo Center 90 South Seventh Street Minneapolis, MN 55402-3901 612/766-7046

Dated: February 28, 2002 M2:20446234.01